Cryoport, Inc. (BUL:CKX)
Bulgaria · Delayed Price · Currency is EUR | Market Cap | 921.55M +141.2% |
| Revenue (ttm) | 169.46M +11.8% |
| Net Income | -43.41M |
| EPS | -0.89 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 19.45 |
| Day's Range | n/a |
| 52-Week Range | 14.45 - 19.45 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Mar 3, 2027 |
About Cryoport
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The comp... [Read more]
News
Cryoport price target raised to $22 from $20 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Cryoport (CYRX) to $22 from $20 and keeps a Buy rating on the shares. The company delivered a strong quarter, with revenue growing…
Cryoport price target raised to $20 from $17 at KeyBanc
KeyBanc analyst Paul Knight raised the firm’s price target on Cryoport (CYRX) to $20 from $17 and keeps an Overweight rating on the shares. The firm notes the cell therapy…
Cryoport Earnings Call Transcript: Q3 2026
Q3 revenue rose 14% YoY to $50.2M, with strong services and commercial cell and gene therapy activity. Adjusted EBITDA remained positive for a second quarter, and FY2026 revenue guidance increased to $197M-$199M.
Cryoport Slides: Q3 2026
Cryoport has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Cryoport Earnings release: Q3 2026
Cryoport released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Cryoport Quarterly report: Q3 2026
Cryoport has published its Q3 2026 quarterly earnings report on November 5, 2026.
Cryoport reports Q3 EPS (25c), consensus (17c)
Reports Q3 revenue $50.2M, consensus $48.69M. Cryoport (CYRX) held $393.1M in cash, cash equivalents, and short-term investments as of September 30, 2026. CEO Jerrell Shelton stated, “Cryoport deliver...
Cryoport now sees 2026 revenue $197M-$199M, consensus $195.47M
16:34 EST Cryoport (CYRX) now sees 2026 revenue $197M-$199M, consensus $195.47M
Cryoport Reports Third Quarter 2026 Financial Results
Third quarter revenue grew 14% year-over-year to $50.2 million Commercial Cell and Gene Therapy revenue increased 20% year-over-year Supporting a record 788 global clinical trials and 23 commercially ...
Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026
NASHVILLE, Tenn., Oct. 22, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for t...
Cryoport price target raised to $26 from $25 at BTIG
BTIG analyst David Larsen raised the firm’s price target on Cryoport (CYRX) to $26 from $25 and keeps a Buy rating on the shares after hosting its management team for…
Cryoport price target raised to $19 from $16 at Guggenheim
Guggenheim raised the firm’s price target on Cryoport (CYRX) to $19 from $16 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for select…
Cryoport management to meet with BTIG
Healthcare IT & Digital Health Analyst Larsen holds a Field Trip to New York on October 7 and New Jersey on October 8 hosted by BTIG.
Cryoport price target raised to $19 from $15 at Needham
Needham raised the firm’s price target on Cryoport (CYRX) to $19 from $15 and keeps a Buy rating on the shares. The company’s Q2 sales beat consensus and management reiterated…
Cryoport price target raised to $16 from $12 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Cryoport (CYRX) to $16 from $12 and keeps a Buy rating on the shares.
Cryoport price target raised to $21 from $15 at Roth Capital
Roth Capital analyst Richard Baldry raised the firm’s price target on Cryoport (CYRX) to $21 from $15 and keeps a Buy rating on the shares. Cryoport delivered a strong Q2…
Cryoport Earnings Call Transcript: Q2 2026
Q2 2026 saw $49M in revenue, 15% growth in Life Sciences Services, and positive Adjusted EBITDA. Guidance for 2026 is reaffirmed at $192M-$196M, with strong demand, new product launches, and operational milestones supporting sustainable growth.
Cryoport Slides: Q2 2026
Cryoport has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Cryoport Earnings release: Q2 2026
Cryoport released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cryoport Quarterly report: Q2 2026
Cryoport has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cryoport reports Q2 EPS (20c), consensus (18c)
Reports Q2 revenue $49M, consensus $48.21M. Jerrell Shelton, CEO of Cryoport (CYRX), commented, “Our revenue momentum over the past several periods continued into the second quarter, with total revenu...
Cryoport Reports Second Quarter 2026 Financial Results
Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global ...
Cryoport price target raised to $25 from $17 at BTIG
BTIG raised the firm’s price target on Cryoport (CYRX) to $25 from $17 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for t...
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR...